Previous close | 0.1830 |
Open | 0.2680 |
Bid | 0.0000 x 900 |
Ask | 0.0000 x 3000 |
Day's range | 0.2680 - 0.2680 |
52-week range | 0.1510 - 0.4000 |
Volume | |
Avg. volume | 2,703 |
Market cap | 30.357M |
Beta (5Y monthly) | 1.38 |
PE ratio (TTM) | 0.03 |
EPS (TTM) | 10.1700 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613. EOM613 is a peptide-nucleic acid-based broad spectrum immune regulating agent that acts on both key pro-inflammatory and anti-inflammatory cytokines with potential therapeutic utility in treating a variety of acute and chronic inflammatory conditions.